Activity of tigecycline and comparators against recent clinical isolates of Finegoldia magna from Europe.
A total of 206 clinical isolates of Finegoldia magna were collected during the period 2007-2009 from six European countries. The majority of isolates were from body fluids (n = 83; 40.3%) or wounds (n = 82; 39.8%). All isolates were susceptible to tigecycline, meropenem, metronidazole and piperacillin / tazobactam, though susceptibility to penicillin (86.4-87.4%) and clindamycin (78.2-93.3%) were more variable.